Adverse endocrine and metabolic effects of psychotropic drugs: Selective clinical review

CNS Drugs

Volumn 23, Issue 12, 2009, Pages 1003-1021

  Bhuvaneswar, Chaya G ^a   Baldessarini, Ross J ^b,c   Harsh, Veronica L ^d   Alpert, Jonathan E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCLEAN HOSPITAL   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DESMOPRESSIN; DIURETIC AGENT; FLUOXETINE; LITHIUM; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXCARBAZEPINE; PALIPERIDONE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ADJUVANT THERAPY; ANORGASMIA; ANXIETY DISORDER; CLINICAL ASSESSMENT; DIABETES INSIPIDUS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FLUID BALANCE; HORMONAL REGULATION; HUMAN; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTENSION; HYPOCALCEMIA; HYPONATREMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; MEDICAL CARE; MENTAL HEALTH CARE; MENTAL PATIENT; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; VIRILIZATION; WEIGHT REDUCTION;

ENDOCRINE SYSTEM DISEASES; HUMANS; METABOLIC DISEASES; PRACTICE GUIDELINES AS TOPIC; PSYCHOTROPIC DRUGS; RISK ASSESSMENT;

EID: 71449121650     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11530020-000000000-00000     Document Type: Review

References (248)

1. Larsen PR, Kronenberg HM, Melmed S, et al., editors. Williams textbook of endocrinology. 10th ed. Philadelphia (PA): Saunders, 2003
2. Polishuk WZ, Kulcsar S. Effects of chlorpromazine on pi-tuitary function. J Clin Endocrinol Metab 1956; 16: 292-293
3. Wieck A, Haddad PM. Antipsychotic-induced hyperpro-lactinaemia in women: pathophysiology, severity and consequences: selective literature review. Br J Psychiatry 2003; 182: 199-204
4. Bushe C, Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical anti-psychotics. J Psychopharmacol 2007; 21: 768-769
5. Langer G, Sachar EJ, Nathan RS, et al. Dopaminergic factors in human prolactin regulation: a pituitary model for the study of a neuroendocrine system in man. Psycho-pharmacology 1979; 65: 161-164
6. Fowlie S, Burton J. Hyperprolactinaemia and non-puerperal lactation associated with clomipramine. Scott Med J 1987; 32: 52-53
7. Barbaro D, Faggionato F, Pallini S, et al. Verapamil acute administration: a new dynamic test in hyperprolactinemic states. Metabolism 1999; 48: 1351-1356
8. Ziambaras K, Dagogo-Jack S. Tumor-grade hyperpro-lactinemia induced by multiple medications in the setting of renal failure. Endocrinol Pract 1999; 5: 139-142
9. Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am 2001; 30: 586-610
10. Orlando G, Brunetti L, Vacca M. Ritonavir and saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro. Int J Immunopathol Pharmacol 2002; 15: 65-68
11. Papakostas GI, Miller KK, Petersen T, et al. Serum pro-lactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluox-etine. J Clin Psychiatry 2006; 67: 952-957
12. Monteleone P, Maj M, Ariano MG, et al. Prolactin re-sponse to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 1988; 96: 223-226
13. Isojarve JI, Pakarinen AJ, Myllyla VV. Effects of carba-mazepine on the hypothalamic-pituitary-gonadal axis in male patients with epilepsy: prospective study. Epilepsia 1989; 30: 446-452
14. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992; 11: 851-856
15. Hirschfeld RM. Management of sexual side effects of antidepressant therapy. J Clin Psychiatry 1999; 60 Suppl. 14: 27-35
16. El Khoury A, Tham A, Mathe AA, et al. Decreased plasma prolactin release in euthymic lithium-treated women with bipolar disorder. Neuropsychobiology 2003; 48: 14-18
17. Van Cauter E, Linkowski P, Kerkhofs M, et al. Circadian and sleep-related endocrine rhythms in schizophrenia. Arch Gen Psychiatry 1991; 48: 348-356
18. Kopacek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. Neuroendocrinol Lett 2004; 25: 419-422
19. Paparrigopoulos T, Liappas J, Tzavellas E, et al. Amisul-pride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 92-96
20. Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989; 9: 247-253
21. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 2006; 21: 529-532
22. Lai YC, Chou CC, Chen CH, et al. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone. J Clin Psychopharmacol 2007; 27: 523-524
23. Maguire GA. Prolactin elevation with antipsychotic medi-cations: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 Suppl. 4: 56-62
24. Baldessarini RJ, Tarazi FI. Chapter 18: pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Press, 2005: 461-500
25. Costa AM, de Lima MS, Faria M. Naturalistic, nine-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia. J Psychopharmacol 2007; 21: 165-170
26. Saldana SN, Delgado SV. Ziprasidone-associated galac-torrhea in an adolescent female. J Child Adolesc Psycho-pharmacol 2007; 17: 259-260
27. Kim KS, Pae CU, Chae JH, et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63: 408-413
28. Wahl R, Ostroff R. Reversal of symptomatic hyperprolac-tinemiaby aripiprazole. Am J Psychiatry 2005; 162: 1542-1543
29. Shim JC, Shin JG, Kelly DL. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: placebo-controlled trial. Am J Psychiatry 2007; 164: 1404-1410
30. Wolf J, Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 2007; 32: 197-198
31. Molitch M. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80: 1050-1057
32. Staller J. Effect of long-term antipsychotic treatment on pro-lactin. J Child Adolesc Psychopharmacol 2006; 16: 317-326
33. Brown WA, Laughren TP. Tolerance to the prolactin-elevating effects of neuroleptics. Psychiatry Res 1981; 5: 317-322
34. Kinon BJ, Gilmore JA, Liu H, et al. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 2003; 28: 55-68
35. Alpert M, Diamond F, Kesselman M. Correlation between extrapyramidal and therapeutic effects of neuroleptics. Compr Psychiatry 1977; 18: 333-336
36. McEvoy JP. The neuroleptic threshold as a marker of minimum effective neuroleptic dose. Compr Psychiatry 1986; 27: 327-335
37. Stevens JR, Kysmissis PI, Baker AJ. Elevated prolactin levels in male youths treated with risperidone and quetia-pine. J Child Adolesc Psychopharmacol 2005; 15: 893-900
38. Holzer M, Eap CB. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psycho-pharmacol 2006; 26: 167-171
39. Lee BH, Kim YK. Relationship between prolactin response and clinical efficacy of risperidone in acute psychotic in-patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 658-662
40. Misra M, Papakostas GI, Klibanski A. Effects of psychia-tric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607-1618
41. Romeo JH, Ybarra J. Hypogonadal hypogonadism and osteoporosis in men. Nurs Clin No Am 2007; 42: 87-99
42. Haddad PM, Wieck A. Antipsychotic-induced hyperpro-lactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291-2314
43. Thangavelu K, Geetanjali S. Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications. Exp Clin Psychopharmacol 2006; 14: 459-460
44. Prabhakar VK, Davis JR. Hyperprolactinaemia. Best Pract Res Clin Obstet Gynaecol 2008; 22: 341-353
45. Loh C, Leckband SG, Meyer JM. Risperidone-induced retrograde ejaculation: case report and review of the literature. Int Clin Psychopharmacol 2004; 19: 111-112
46. Aleem M, Choudhari J, Padwal V. Hyperprolactinemia affects spermiogenesis in adult male rats. J Endocrinol Invest 2005; 28: 39-48
47. Giagulli VA, Carbone D. Hormonal control of inhibin-B in men. J Endocrinol Invest 2006; 29: 706-713
48. Whalley LJ, Christie JE, Blackwood DH, et al. Disturbed endocrine function in the psychoses: disordered homeo-stasis or disease process? Br J Psychiatry 1989; 155: 455-461
49. Harvey PW, Everett DJ, Springall CJ. Hyperprolactin-aemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer. Hum Exp Toxicol 2006; 25: 395-404
50. Szarfman A, Tonning JM, Levine JG, et al. Atypical anti-psychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26: 748-758
51. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006; 45: 771-791
52. Nakajima M, Terao T, Iwata N. Switching female schizo-phrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry 2005; 38: 17-19
53. Kinon MJ, Ahl J, Liu-Siefert H. Improvement in hyper-prolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional anti-psychotics or risperidone to olanzapine. Psychoneuro- endocrinology 2006; 31: 577-588
54. Rego MD, Giller EL. Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. J Clin Psychiatry 1989; 50: 143-144
55. Smith S. Neuroleptic-associated hyperprolactinemia: can it be treated with bromocriptine? J Reprod Med 1992; 37: 737-740
56. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003; 46: 349-362
57. Javaid MK, Holt RI. Understanding osteoporosis. J Psy-chopharmacol 2008; 22 (2 Suppl.): 38-45
58. Holt RI. A context for psychiatrists: medical causes and consequences of hyperprolactinemia. J Psychopharmacol 2002; 22 (2 Suppl.): 28-37
59. Samllridge RC, Whorton NE, Burman KD, et al. Effects of exercise and physical fitness on the pituitary-thyroid axis and on prolactin secretion in male runners. Metabolism 1985; 34: 949-954
60. Eskildsen PC, Kirkegaard CB. Influence of thyroid disorders on the dopaminergic regulation of prolactin, thyrotropin and growth hormone. J Endocrinol Invest 1985; 8: 427-431
61. Ellison DH, Berl T. Clinical practice: the syndrome of in-appropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072
62. Pimentel L. Medical complications of oncologic disease. Emerg Med Clin North Am 1993 May; 11: 407-419
63. Dundas B, Harris M, Narasimhan M. Psychogenic poly-dipsia review: etiology, differential, and treatment. Curr Psychiatry Rep 2007; 9: 236-241
64. Ananth J, Lin KM. SIADH: a serious side effect of psy-chotropic drugs. Int J Psychiatr Med 1987; 16: 401-407
65. Davison P, Wardrope J. Acute amitriptyline withdrawal and hyponatremia. Drug Saf 1993; 8: 78-80
66. Gandelman MS. Review of carbamazepine-induced hypo-natremia. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 211-233
67. Rider JM, Mauger TF, Jameson JP. Water handling in patients receiving haloperidol decanoate. Ann Pharmaco-ther 1995; 29: 663-666
68. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiure-tic hormone associated with the use of selective serotonin reuptake inhibitors: review of spontaneous reports. Can Med Assoc J 1996; 155: 519-527
69. Siegel A, Baldessarini RJ, Klepser MB, et al. Primary and drug-induced disorders of water homeostasis in psychiatric patients: principles of diagnosis and management. Harvard Rev Psychiatry 1998; 6: 190-200
70. Kalantar-Zadeh K, Nguyen MK, Chang R, et al. Fatal hyponatremia in a young woman after ecstasy ingestion. Nat Clin Pract Nephrol 2006; 2: 283-288
71. Mann K, Rossbach W, Muller MJ, et al. Noctournal hor-mone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 2006; 31: 256-264
72. Romero S, Pintor L, Serra M. Syndrome of inappropriate secretion of antidiuretic hormone due to citalopram and venlafaxine. Gen Hosp Psychiatry 2007; 29: 81-84
73. Matsumura M, Yamaguchi M, Sato T. Severe hypona-tremia in a patient treated with levomepromazine and carbamazepine [letter]. Intern Med 2001; 40: 459
74. Atalay A, Turhan N, Aki OE. A challenging case of syn-drome of inappropriate secretion of antidiuretic hormone in an elderly patient secondary to quetiapine. South Med J 2007; 100: 832-833
75. Vucicevic Z, Degoricija V, Alfirevic Z, et al. Fatal hypo-natremia and other metabolic disturbances associated with psychotropic drug polypharmacy. Int J Clin Pharmacol Ther 2007; 45: 289-292
76. Sarma S, Ward W, O'Brien J, et al. Severe hyponatremia associated with desmopressin nasal spray to treat cloza-pine-induced nocturnal enuresis. Aust NZ J Psychiatry 2005; 39: 949-950
77. Weaver A, Dobson P. Nocturnal enuresis in children. J Fam Health Care 2007; 17: 159-161
78. Petersson I, Nilsson G, Hansson BG, et al. Water intoxi-cation associated with non-steroidal anti-inflammatory drug therapy. Acta Med Scand 1987; 221: 221-223
79. Mann SJ. The silent epidemic of thiazide-induced hypo-natremia. J Clin Hypertens (Greenwich) 2008 Jun; 10 (6): 477-484
80. Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999; 281: 2299-2304
81. Fried LF, Palevsky PM. Hyponatremia and hyperna-tremia. Med Clin North Am 1997; 81: 585-609
82. Lane RM. SSRIs and hyponatremia. Br J Clin Pract 1997; 51: 144-146
83. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf 1999; 21: 449-456
84. Sze L, Ulrich B, Brandle M. Severe hypernatremia due to nephrogenic diabetes insipidus: life-threatening side effect of chronic lithium therapy. Exp Clin Endocrinol Diabet 2006; 114: 596-598
85. Hetmar O, Rafaelsen OJ. Lithium: long-term effects on the kidney. Acta Psychiatr Scand 1987; 76: 193-198
86. Paw H, Slingo ME, Tinker M. Late onset nephrogenic diabetes insipidus following cessation of lithium therapy. Anaesth Intensive Care 2007; 35: 278-280
87. Raedler TJ, Wiedemann K. Lithium-induced nephro-pathies. Psychopharmacol Bull 2007; 40: 134-149
88. Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 2006; 13: 96-104
89. Livingston C, Rampes H. Lithium: review of its metabolic adverse effects. J Psychopharmacol 2006; 20: 347-355
90. Henderson DC, Goff DC. Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biol Psychiatry 1994; 36: 768-770
91. Spears NM, Leadbetter RA, Shutty Jr MS, et al. Treatment of polydipsia and hyponatremia in psychiatric patients: can clozapine be a new option? Neuropsychopharmaco-logy 1995; 12: 133-138
92. Canuso CM, Goldman MB. Clozapine restores water balance in schizophrenic patients with polydipsia-hyponatremia syndrome. J Neuropsychiatry Clin Neuro-sci 1999; 11: 86-90
93. Adam P. Evaluation and management of diabetes in-sipidus. Am Fam Physician 1997; 55: 2146-2153
94. Finch CK, Kelley KW, Williams RB. Treatment of lithium-induced diabetes insipidus with amiloride. Pharmaco-therapy 2003; 23: 546-550
95. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health 2006; 2: 23-28
96. Ramschak-Schwartzer S, Radkohl W, Stiegler C, et al. In-teraction between psychotropic drugs and thyroid hormone metabolism: overview. Acta Med Austriaca 2000; 27: 8-11
97. Surks MI, Sievert R. Drugs and thyroid function. New Engl J Med 1995; 333: 1688-1694
98. Eiris-Punal J, Del Rio-Garma M, Del-Rio Garma MC, et al. Long term treatment of children with epilepsy with valproate or carbamazapine may cause subclinical hy-pothyroidism. Epilepsia 1999; 45: 1106-1115
99. Benedetti MS, Whomsley R, Baltes E, et al. Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferease induction. Eur J Clin Pharmacol 2005 Dec; 61: 863-872
100. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia treated with quetiapine, risperi-done, or fluphenazine. J Clin Psychiatry 2005; 66: 80-84
101. McCracken JT, Hanna GL. Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment. J Child Adolesc Psychopharmacol 2005; 15: 581-587
102. Liappas J, Paparrigopoulos T, Mourikis I, et al. Hypo-thyroidism induced by quetiapine: a case report. J Clin Psychopharmacol 2006 Apr; 26: 208-209
103. Lasser RA, Baldessarini RJ. Thyroid hormones in depres-sive disorders: reappraisal of clinical utility. Harvard Rev Psychiatry 1997; 4: 291-305
104. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. New Engl J Med 2001; 344: 1743-1749
105. Kleiner J, Altshuler L, Hendrick V, et al. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60: 249-255
106. Kahn DA, Sachs GS, Printz DJ, et al. Medication treat-ment guidelines of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Prac 2000; 6: 197-211
107. Fagiolini A, Kupfer DJ, Scott J, et al. Hypothyroidism in patients with bipolar I disorder treated primarily with lithium. Epidemiol Psichiatr Soc 2006 Apr-Jun; 15 (2): 123-127
108. Bunevicius R, Jakubonien N, Jurkevicius R, et al. Thy-roxine versus thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves' disease. Endocrine 2002; 18: 129-133
109. Siegmund W, Spieker K, Weike AI, et al. Replacement therapy with levothyroxine plus triiodothyronine is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endo-crinol 2004; 60: 750-757
110. Khandwala HM, Van Uum S. Reversible hypercalcemia and hyperparathyroidism associated with lithium therapy: case report and review of literature. Endocr Pract 2006; 12: 54-58
111. Suda DA, Schlickman PW, Perry PJ. Clinical dilemma of lithium-induced hyperparathyroidism in a treatment-responsive patient. Ann Clin Psychiatry 2006; 18: 131-132
112. Sloand JA, Shelly MA. Normalization of lithium-induced hypercalcemia and hyperparathyroidism with cinalcet hydrochloride. Am J Kidney Dis 2006; 48: 832-837
113. Chiba Y, Satoh K, Ueda S, et al. Marked improvement of psychiatric symptoms after parathyroidectomy in elderly primary hyperparathyroidism. Endocrine J 2007; 54: 379-383
114. Caksen H, Dulger H, Cesur Y, et al. Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy. Int J Neurosci 2003; 113: 1213-1217
115. Nicolaidou P, Georgouli H, Kotsalis H, et al. Effects of anticonvulsant therapy on vitamin-D status in children: prospective monitoring study. J Child Neurol 2006; 21: 205-209
116. Haney EM, Chan BK, Diem DL, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167: 1246-1251
117. Goodman SB, Jiranek W, Petrow E, et al. Effects of med-ications on bone. J Am Acad Orthop Surg 2007; 15: 450-460
118. Halbreich U. Osteoporosis, schizophrenia and anti-psychotics: need for a comprehensive multifactorial evaluation. CNS Drugs 2007; 21: 641-657
119. Laekeman G, Zwaenepoel L, Reyntens J, et al. Osteo-porosis after combined use of a neuroleptic and anti-depressants. Pharm World Sci 2008; 30: 613-616
120. Petronijevic M, Petronijevic N, Ivkovic M, et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone 2008; 42: 582-590
121. Jayasinghe Y, Grover SR, Zacharin M. Current concepts in bone and reproductive health in adolescents with anorexia nervosa. BJOG 2008; 115: 304-315
122. Drake MT, Clarke BL, Khosla S. Bisphosphonates: me-chanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032-1045
123. Stimmel GL, Gutierrez MA. Sexual dysfunction and psychotropic medications. CNS Spectr 2006; 11 Suppl. 9: 24-30
124. Joffe H, Hall JE, Cohen LS, et al. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harvard Rev Psychiatry 2003; 11: 99-108
125. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078-1086
126. Joffe H, Cohen LS, Suppes T, et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features. Biol Psychiatry 2006; 60: 1378-1381
127. Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomized, controlled trials. J Affect Disord 2005; 88: 241-254
128. Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 2008; 23: 321-326
129. Balon R. SSRI-associated sexual dysfunction. Am J Psy-chiatry 2006; 163: 1504-1509
130. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119-122
131. Cicero AF, Piacente S, Plaza A, et al. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologica 2002; 34: 177-179
132. Yeh KY, Pu HF, Kaphle K, et al. Gingko biloba extract enhances male copulatory behavior and reduces serum prolactin levels in rats. Horm Behav 2007; 53: 225-231
133. Auger RR, Goodman SH, Silber MH, et al. Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: case-control study. Sleep 2005; 28: 667-672
134. Baptista T, ElFakih Y, Uzcagetgui E, et al. Pharmacolo-gical management of atypical antipsychotic-induced weight gain. CNS Drugs 2008; 22: 477-495
135. Hainer V, Kabrnova K, Aldhoon B, et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann NY Acad Sci 2006; 1083: 252-269
136. Lader M. Pharmacotherapy of mood disorders and treat-ment discontinuation. Drugs 2007; 67: 1657-1663
137. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: pooled analysis of selective serotonin reuptake inhibitor-and impramine-controlled trials. J Clin Psychiatry 2001; 62: 256-260 (Pubitemid 32428764)
138. Hecht-Orzack M, Cole JO, Friedman L, et al. Weight changes with antidepressants: comparison of amitripty-line and trazodone. Neuropsychobiology 1986; 15 Suppl. 1: 28-30
139. Baldessarini RJ. Chapter 17: drug therapy of depression and anxiety disorders. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed. New York: McGraw-Hill Press, 2005: 429-459
140. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-636
141. Citrome LL. Increase in risk of diabetes mellitus from ex-posure to second-generation antipsychotic agents. Drugs Today 2004; 40: 445-464
142. Harrison-Woolrych M, Garcia-Quiroga J, Ashton J, et al. Safety and usage of atypical antipsychotic medicines in children: nationwide prospective cohort study. Drug Saf 2007; 30: 569-579
143. Logue DD, Gonzalez N, Heligman SD, et al. Hyperglyce-mia in a 7-year-old child treated with aripiprazole. Am J Psychiatry 2007; 164: 173-174
144. Parent MM, Roy S, Sramek J, et al. Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm 1986; 20: 873-875
145. Goodnick PJ, Henry JH, Buki VM. Treatment of depres-sion in patients with diabetes mellitus. J Clin Psychiatry 1995; 56: 128-136
146. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight-gain: comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696
147. Luef GJ, Lechleitner M, Bauer G, et al. Valproic acid modulates islet cell insulin secretion: possible mechanism of weight-gain in epilepsy patients. Epilepsy Res 2003; 55: 53-58
148. Lagace DC, McLeod RS, Nachtigal MW. Valproic acid inhibits leptin secretion and reduces leptin messenger ribo-nucleic acid levels in adipocytes. Endocrinology 2004; 145: 5493-5503
149. Bowden CL, Calabrese JR, Ketter TA, et al. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Am J Psychiatry 2006; 163: 1199-1201
150. Aliyazicioglu R, Kural B, Colak M, et al. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. Tohoku J Exp Med 2007; 213: 79-87
151. Correll CU. Weight gain and metabolic effects of mood-stabilizers and antipsychotics in pediatric bipolar disorder: systematic review and pooled analysis of short term trials. J Am Acad Child Adolesc Psychiatry 2007; 46: 687-700
152. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. CNS Spectr 2007; 12 Suppl. 17: 12-20
153. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophrenia Res 2008; 99: 13-22
154. Strassnig M, Miewald J, Keshavan M, et al. Weight-gain in newly diagnosed first-episode psychosis patients and healthy comparison: one year analysis. Schizophrenia Res 2007; 93: 90-98
155. Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine vs. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192: 135-143
156. Torrent C, Amann B, Sanchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand 2008; 118: 4-18
157. Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007; 48: 1366-1370
158. Dunner DL. Safety and tolerability of emerging pharma-cological treatments for bipolar disorder. Bipolar Disord 2005; 7: 307-325
159. Fava M. Weight-gain and antidepressants. J Clin Psy-chiatry 2000; 61 Suppl. 11: 37-41
160. Lakka HM, Laaksonen DE, Lakka TA, et al. Metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716
161. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of metabolic syndrome: American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
162. Hardy TA, Marquez E, Kryzhanovskaya L, et al. Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. J Clin Psychopharmacol 2006; 26: 405-408
163. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68 Suppl. 4: 8-13
164. McElroy SL, Kotwal R, Malhotra S, et al. Are mood dis-orders and obesity related? Review for the mental health professional. J Clin Psychiatry 2004; 65: 634-651
165. Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58: 175-189
166. Holt RI, Bushe C, Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psy-chopharmacol 2005; 19 Suppl. 6: 56-65
167. Amamoto T, Kumai T, Nakaya S, et al. The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine. J Pharmacol Sci 2006; 102: 213-219
168. Ellingrod VL, Miller D, Taylor SF, et al. Metabolic syn-drome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for methylenetetrahy-drofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia Res 2008; 98: 47-54
169. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr Scand 2003; 108: 208-214
170. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl. 18: 27-35
171. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: comprehensive review. Schizophrenia Res 2004; 70: 1-17
172. Tarricone I, Casoria M, Gozzi BF, et al. Metabolic risk factor profile associated with use of second generation antipsychotics: cross sectional study in a community mental health center. BMC Psychiatry 2006; 6: 11-19
173. De Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Res 2007; 92: 95-102
174. Henderson DC. Clozapine: diabetes mellitus, weight-gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl. 23: 39-44
175. Wirshing DA, Boyd JA, Meng LR, et al. Effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865
176. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psycho-pharmacology 2003; 170: 157-166
177. Markham-Abedi C, de Leon J. Hypertriglyceridemia as-sociated with direct effects of olanzapine rather than with weight gain: case report. J Clin Psychiatry 2006; 67: 1473-1474
178. Procyshyn RM, Wasan KM, Thornton AE, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007; 32: 331-338
179. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol 2007; 27: 374-379
180. Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008; 69: 1166-1175
181. Rachenzauner M, Haberlandt E, Scholl Burgi S, et al. Ef-fect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res 2008; 80: 142-149
182. Selikson S, Damus K, Hamerman DJ. Risk factors asso-ciated with immobility. Am Geriatr Soc 1988; 36: 707-712
183. Whyte EM, Drayer RA, Soreca I, et al. Medical burden in late-life bipolar and major depressive disorders. Am J Geriatr Psychiatry 2008; 16: 194-200
184. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27-35
185. Aydin K, Serdaroglu A, Okuyaz C, et al. Serum insulin, leptin and neuropeptide y levels in epileptic children treated with valproate. J Child Neurol 2005; 20: 848-851
186. Haupt DW, Luber A, Maeda J, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 2005; 30: 184-191
187. Baptista T, Davila A, El Fakih Y, et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol 2007; 22: 205-211
188. Baptista T, Sandia I, Lacruz A, et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol 2007; 22: 69-76
189. Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: risk predictors of weight-gain. Eur J Paediatr Neurol 2009; 13: 261-268
190. Mohs ME, Watson RR, Leonard-Green T. Nutritional effects of marijuana, heroin, cocaine, and nicotine. J Am Diet Assoc 1990; 90: 1261-1267
191. Lynch ME, Young J, Clark AJ. Case series of patients using medical marihuana for management of chronic pain under Canadian Marihuana Medical Access Regulations. J Pain Symp Manage 2006; 32: 497-501
192. Berkey CS, Rockett HR, Colditz GA. Weight-gain in older adolescent females: the internet, sleep, coffee, and alcohol. J Pediatr 2008; 153: 635-639
193. Han DH, Bolo N, Daniels MA, et al. Craving for alcohol and food during treatment for alcohol dependence: modulation by T allele of 1519T-C GABA-A-a6. Alcohol Clin Exp Res 2008; 32: 1593-1599
194. Le-Niculescu H, McFarland MJ, Ogden CA, et al. Phe-nomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 134-166
195. Rathbone J, Variend H, Mehta H. Cannabis and schizo-phrenia. Cochrane Database Syst Rev 2008 Jul 16: (3) CD004837
196. Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 2004; 19: 271-273
197. Garman PM, Ried LD, Bengston MA, et al. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc 2007; 47: 373-378
198. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Ari-piprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: open-label pilot study. Prog Neuro-psychopharmacol Biol Psychiatry 2007; 31: 373-377
199. Spurling RD, Lamberti JS, Olsen D, et al. Changes in me-tabolic parameters with switching to aripiprazole from another second-generation antipsychotic: retrospective chart review. J Clin Psychiatry 2007; 68: 406-409
200. Kontos N, Freudenreich O, Querques J. Using a medical model with psychotic patients. Am J Psychiatry 2006; 163: 1646-1647
201. Chen CH, Chiu CC, Huang MC, et al. Metformin for me-tabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2007; 32: 925-931
202. Goff DC. Integrating general health care in private com-munity psychiatry practice. J Clin Psychiatry 2007; 68 Suppl. 4: 49-54
203. Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: investigation of efficacy and tolerability in overweight and obese women. Obesity Res 2001; 9: 544-551
204. Gadde KM, Zhang W, Foust MS. Bupropion treatment of olanzapine-associated weight gain: open-label, prospective trial. J Clin Psychopharmacol 2006; 26: 409-413
205. Bray GA. Medical therapy for obesity: current status and future hopes. Med Clin North Am 2007; 91: 1225-1253
206. Wooltorton E. Obesity drug sibutramine (Meridia): hyper-tension and cardiac arrhythmias. CMAJ 2002; 166: 1307-1308
207. Henderson DC, Copeland PM, Daley TB, et al. Double-blind, placebo-controlled trial of sibutramine for olanza-pine-associated weight gain. Am J Psychiatry 2005; 162: 954-962
208. Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics 2007; 120: 147-157
209. Henderson DC, Fan X, Copeland PM, et al. Double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115: 101-105
210. Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: practical guide for its safe use. Obesity Rev 2007; 62: 88-96
211. Rubio MA, Gargallo M, Isabel Millan A, et al. Drugs in the treatment of obesity: sibutramine, orlistat and rimo-nabant. Pub Health Nutr 2007; 10: 1200-1205
212. Cordeiro Q, Vallada H. Sibutramine-induced mania epi-sode in a bipolar patient. Int J Neuropsychopharmacol 2002; 5: 283-284
213. Litvan L, Alcoverro-Fortuny O. Sibutramine and psy-chosis. J Clin Psychopharmacol 2007; 27: 726-727
214. Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: case report and pathophysiologic correlation. J Psychosom Res 2008; 64: 107-109
215. Trakas K, Shear NH. Serotonin syndrome risk with anti-obesity drug [letter]. Can J Clin Pharmacol 2000; 7: 216
216. Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: multicentric, double-blind, placebo-controlled trial. Schizophrenia Res 2007; 93: 99-108
217. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type-2 diabetes: randomized, double-blind, placebo-controlled study. Int J Obes 2007; 31: 138-146
218. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight-gain: randomized controlled trial. JAMA 2008; 299: 185-193
219. Chengappa RKN, Schwarzman LK, Hulihan JF, et al.; Janssen Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1698-1706
220. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorders. J Clin Psychiatry 2007; 68: 1324-1332
221. McElroy SL, Frye MA, Altschuler LL, et al. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight-gain in overweight or obese patients with bipolar disorders. Bipolar Disord 2007; 9: 426-434
222. Tramontina S, Zeni CP, Pheula G, et al. Topiramate in adolescents with juvenile bipolar disorder presenting with weight gain due to atypical antipsychotics or mood stabilizers: an open clinical trial. J Child Adolesc Psycho-pharmacol 2007; 17: 129-134
223. Gualtieri CT, Johnson LG. Cognitive neurocognitive ef-fects of five psychotropic anticonvulsants and lithium. MedGenMed 2006; 8: 46-47
224. Schrooyen M. Acute glaucoma originating from medica-tion. Bull Soc Belge Ophtalmol 2007; 304: 125-131
225. Gadde KM, Yonish GM, Foust MS, et al. Combination therapy of zonisamide and bupropion for weight reduc-tion in obese women: preliminary, randomized, open-label study. J Clin Psychiatry 2007; 68: 1226-1229
226. Woo J, Sea MM, Tong P, et al. Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with orlistat. J Eval Clin Pract 2007; 13: 853-859
227. Joffe G, Takala P, Tchoukhine E, et al. Orlistat in cloza-pine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69: 706-711
228. Werneke U, Taylor D, Sanders TA. Options for pharma-cological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002; 17: 145-160
229. Scheen AJ. Cannabinoid-1 receptor antagonists in type-2 diabetes. Best Pract Res Clin Endocrinol Metab 2007; 21: 535-553
230. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet 2007; 370: 1671-1672
231. Vemuri VK, Janero DR, Makriyannis A. Pharmacother-apeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 2008; 93: 671-686
232. Gracious BL, Krysiak TE, Youngstrom EA. Amantadine treatment of psychotropic-induced weight-gain in children and adolescents: case series. J Child Adolesc Psy-chopharmacol 2002; 1: 249-257
233. Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 2005; 162: 1744-1746
234. Henderson DC, Louie PM, Koul P, et al. Modafinil-associated weight loss in a clozapine-treated schizo-affective disorder patient. Ann Clin Psychiatry 2005; 17: 95-97
235. Makris AP, Rush CR, Frederich RC, et al. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activi. Appetite 2004; 42: 185-195
236. Hermanussen M, Tresguerres JA. A new anti-obesity drug treatment: first clinical evidence that, antagonizing glutamate-gated Ca2+ ion channels with memantine normalizes binge-eating disorders. Econ Hum Biol 2005; 3: 329-337
237. Schaefer M, Leopold K, Hinzpeter A, et al. Memantine-associated reversal of clozapine-induced weight gain. Pharmacopsychiatry 2007; 40: 149-151
238. American Diabetes Association (ADA), American Psy-chiatric Association (APA), American Association of Clinical Endocrinologists (AACE), North American Association for the Study of Obesity (NAASO). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004; 27: 596-691
239. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and ris-peridone. Psychopharmacology 2005; 183: 383-386
240. Weiden PJ. Switching antipsychotics as a treatment strat-egy for antipsychotic-induced weight-gain and dyslipide-mia. J Clin Psychiatry 2007; 68 Suppl. 4: 34-39
241. Van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008; 69: 472-479
242. Ojala K, Repo-Tiihonen E, Tiihonen J, et al. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 2008; 22: 33-38
243. Weiss AP, Henderson DC, Weilburg JB, et al. Treatment of cardiac risk factors in patients with schizophrenia and diabetes. Psychiatr Serv 2006; 57: 1145-1152
244. Poulin MJ, Chaput JP, Simard V, et al. Management of antipsychotic- induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise program. Aust NZ J Psychiatry 2007; 41: 980-989
245. Henderson DC, Cagliero E, Copeland PM, et al. Elevated hemoglobin-A1C as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia pa-tients receiving atypical antipsychotics. J Clin Psychiatry 2007; 68: 533-541
246. Faulkner G, Cohn TA. Pharmacologic and non-pharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. Can J Psychiatry 2006; 51: 502-511
247. Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry 1999; 60 Suppl. 21: 31-36
248. Faulkner G, Cohn T, Remington G. Interventions to re-duce weight gain in schizophrenia. Cochrane Database Syst Rev 2007 Jan 24; (1): CD005148